RT Journal Article
SR Electronic
T1 Duration of SARS-CoV-2 Sero-Positivity in a Large Longitudinal Sero-Surveillance Cohort: The COVID-19 Community Research Partnership
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.27.21250615
DO 10.1101/2021.01.27.21250615
A1 David Herrington
A1 The COVID-19 Community Research Partnership Study Group
YR 2021
UL http://medrxiv.org/content/early/2021/01/29/2021.01.27.21250615.abstract
AB Background Estimating population prevalence and incidence of prior SARS-CoV-2 infection is essential to formulate public health recommendations concerning the COVID-19 pandemic. However, interpreting estimates based on sero-surveillance requires an understanding of the duration of elevated antibodies following SARS-CoV-2 infection, especially in the large number of people with pauci-symptomatic or asymptomatic disease.Methods We examined >30,000 serology assays for SARS-CoV-2 specific IgG and IgM assays acquired longitudinally in 11,468 adults between April and November 2020 in the COVID-19 Community Research Partnership.Findings Among participants with serologic evidence for infection but few or no symptoms or clinical disease, roughly 50% sero-reverted in 30 days of their initial positive test. Sero-reversion occurred more quickly for IgM than IgG and for antibodies targeting nucleocapsid protein compared with spike proteins, but was not associated with age, sex, race/ethnicity, or healthcare worker status.Interpretation The short duration of antibody response suggests that the true population prevalence of prior SARS-CoV-2 infection may be significantly higher than presumed based on earlier sero-surveillance studies. The impact of the large number of minimally symptomatic COVID-19 cases with only a brief antibody response on population immunity remains to be determined.Funding This publication is supported by the CARES Act, of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $20,000,000. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HHS, or the U.S. Government.Research in contextEvidence before this studyEvidence before this study Previous longitudinal studies of the humoral response to SARS-CoV-2 suggest that people with less severe disease have a more rapid decline of SARS-CoV-2 specific antibodies than people with severe disease. However, these data come from small laboratory-based investigations or studies of convenience samples identified based on symptomatic disease.Added value of this studyAdded value of this study This study provides extensive longitudinal serologic follow-up in a large number of people with serologic evidence of prior infection who had little or no symptoms based on active daily symptom surveillance.Implications of the available evidenceImplications of the available evidence The data indicate that serologic evidence of prior infection in minimally symptomatic people is fleeting, suggesting that cross-sectional sero-surveys have under-estimated the true prevalence of prior infection in populations. The data highlight the challenge of determining transmission dynamics and long-term immunity in asymptomatic cases which likely represents an even larger fraction of all cases of prior SARS-CoV-2 infection than previously presumed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRole of the funding source: This work was supported by a grant from the State of North Carolina funded by the CARES Act, of the U.S. Department of Health and Human Services (HHS). The sponsor had no role in the developing the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Wake Forest University School of Medicine Institutional Review BoardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData Sharing Statement: At end of the study, the databases will be made publicly available in a de-identified manner according to CDC and applicable U.S. Federal policies. (https://covid19crp.bsc.gwu.edu/web/covid19crp/home).